Copper Complexes as Influenza Antivirals: Reduced Zebrafish Toxicity by McGuire, Kelly L. et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
1Chapter
Copper Complexes as Influenza 
Antivirals: Reduced Zebrafish 
Toxicity
Kelly L. McGuire, Jon Hogge, Aidan Hintze, Nathan Liddle, 
Nicole Nelson, Jordan Pollock, Austin Brown, Stephen Facer, 
Steven Walker, Johnny Lynch, Roger G. Harrison  
and David D. Busath
Abstract
Copper complexes have previously been developed to target His37 in influenza M2 
and are effective blockers of both the wild type (WT) and the amantadine-resistant 
M2S31N. Here, we report that the complexes were much less toxic to zebrafish than 
CuCl2. In addition, we characterized albumin binding, mutagenicity, and virus resis-
tance formation of these metal complexes, and employed steered molecular dynamics 
simulations to explore whether the complexes would fit in M2. We also examined 
their anti-viral efficacy in a multi-generation cell culture assay to extend the previ-
ous work with an initial-infection assay, discovering that this is complicated by cell 
culture medium components. The number of copper ions binding to bovine serum 
albumin (BSA) correlates well with the number of surface histidines and BSA binding 
affinity is low compared to M2. No mutagenicity of the complexes was observed when 
compared to sodium azide. After 10 passages of virus in MDCK culture, the EC50 was 
unchanged for each of the complexes, i.e. resistance did not develop. The simulations 
revealed that the compounds fit well in the M2 channel, much like amantadine.
Keywords: medicinal metals, proton transport, plaque assay, Ames, CTX, CPE
1. Introduction
The influenza A M2 protein is a homotetrameric channel [1] that is particularly 
selective for protons [2] and is essential for uncoating of the virus [3]. The proton 
selectivity is due to the cluster of His37 imidazole side chains in the channel [4, 5]. 
This channel has been a primary antiviral target. Amantadine (AMT) and rimanta-
dine (RMT) were highly successful as M2 blockers [6–8], but they became ineffec-
tive in 2005 when a mutation from serine to asparagine at residue 31 (S31N) in M2 
occurred [9, 10].
Attempts have been made to develop variants of AMT, RMT and others that 
could block the V27A, L26F, or S31N mutations [11–14]. We explored a different 
approach that could, in theory, target all functional forms of M2 [15].
Drawing from the observation that divalent cations, particularly copper, block 
M2 current [16] binding in the His37-Trp41 side chain quadruplex [17], divalent 
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copper complexes of AMT were synthesized and found to be effective influenza A 
inhibitors with reduced cytotoxicity compared to CuCl2 [15]. Because Cu
2+ binds 
strongly to imidazole, it was suggested that the Cu2+ complexes also block M2 
through His37-imidazole binding. In addition, the His37 cluster is highly conserved 
in nature [18], making it a prime target in the M2 channel.
The copper ligands developed were based on AMT and the lesser-known, 
equally effective M2 WT blocker, cyclooctylamine (CO) [19, 20], and extended 
via the amine with the functional groups iminodiacetate or iminodiacetamide. Six 
Cu2+ complexes (Figure 1) were synthesized and characterized using NMR, IR, 
MS, UV-Vis, and ICP-MS. The complexes demonstrated H37-specific block of M2 
current in two electrode voltage-clamp (TEVC) studies with low μM potencies. 
The copper-free ligands did not show proton current block, demonstrating that the 
copper was key to the current-blocking process [15].
Because of the reduced toxicity to cultured cells found previously, we were 
interested to learn whether the six metal complexes were toxic to simple organisms. 
Zebrafish embryos were chosen because they have immune and nervous systems 
similar in many ways to more advanced organisms, because they are in an early, 
vulnerable stage of development, and because the compounds are readily adminis-
tered at infection-relevant concentrations in their bathwater. We also explored and 
report additional properties of these copper complexes, including their efficacies in 
the cytopathic effect antiviral assay, their binding to albumin, mutagenicity testing 
in a bacterial assay, virus resistance development when passaged with cell culture 
in the presence of the compounds, and molecular dynamics simulations to explore 
how well the compounds fit in the M2 channel.
2. Materials and methods
2.1 Cytopathic effect assay
Confluent MDCK cells were transferred into 60 wells of a 96-well plate in DMEM 
(Gibco Thermo Scientific Waltham, MA, 4.5 g/L D-Glucose) with 5% Fetal Bovine 
Serum (FBS, Hyclone, Logan, UT). The cells were washed with a diluted solution 
of 50% SEM/50% serumless DMEM. SEM (simple electrolyte medium) consists 
of 4.33 g NaCl, 0.244 g KCl, 0.103 g CaCl2·2H2O, MgCl2·6H2O, Na2HPO4·7H2O, 
NaH2PO4·H2O in 500 ml H2O. The cells were incubated for an hour with activated A/
WS/33 virus and then the media with virus was removed. The SEM/serumless DMEM 
with 100 μM metal complex was added to six wells. The complexes were then serial-
diluted in two-fold increments six times. Six wells were used as positive controls with 
no complex or virus added. Six wells were used as negative controls with only virus 
added and no complex. About 80 μM ribavirin (Sigma-Aldrich, St. Louis, MO) was 
added to six wells as a positive control. The plates were incubated for 48 h at 33C.
Figure 1. 
Copper complexes with the functional groups iminodiacetate or iminodiacetamide extended via the amine to 
either AMT or CO.
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The crystal violet staining technique described previously [21] was used to 
determine the fraction of cells that survived the exposure to the virus. After 48 h, 
the test medium was removed, and the cells were washed three times with 150 μl 
PBS. The cells were stained for 10 min with 50 μl crystal violet solution (0.03% 
crystal violet (w/v) in 20% methanol). The cells were then washed three times with 
150 μl distilled water before adding 100 μl lysis buffer. After 20 min, the optical 
density (OD) of each well was measured at 590 or 620 nm and averaged over the set 
of six wells for each concentration.
Because viral dosing was sufficient to eliminate essentially all cells in treatment-
free controls, their average OD was subtracted as baseline from the average of the 
treated well ODs. The result was divided by the average of the uninfected control 
well ODs to obtain a normalized vitality. Because the vitality can be affected by both 
reduction of virus cytopathic effect and increase of treatment toxicity as concentra-
tion is increased, we fitted the normalized concentration-dependent vitality, V(C), 
with a joint probability function:
  V (C) =  1 _ 
1 +  (  EC 50  _C ) 
 n 1 
 
 1 _ 
1 +  ( C _  CC 50 ) 
 n 2 
 
(1)
Here, EC50 is the 50% effective dose of treatment that prevents viral cytopathic 
effect, CC50 is the 50% cytotoxic dose of the treatment, and n1 and n2 are their 
respective Hill coefficients. If the selectivity index, CC50/EC50, and the Hill coef-
ficients are sufficiently high, this function rises to unity at doses that are sufficient 
to prevent viral replication but below toxic levels. Non-linear least squares fitting 
weighted with standard errors of means was done with the Marquardt algorithm 
in KaleidaGraph4 (Synergy Software, Reading, PA). In practice, it was necessary 
to fix the Hill coefficients to evaluate the effective doses, then manually adjust the 
Hill coefficients to improve the fit (due to low numbers of data points). Hence, the 
reported standard errors of the parameters obtained from the error matrix may be 
underestimated.
2.2 Protein binding assay
Each copper complex was dissolved in 25 ml of water to obtain a 1 mM and 
800 μM solution. All water used in the protein binding assay was collected 
from a Millipore first-generation beige Milli-Q system. These solutions were 
sonicated until the crystals were fully dissolved. Four 1:2 serial dilutions were 
performed from the 800 μM solution to obtain 400, 200, 100, and 50 μM 
solutions, and a 1:5 dilution was performed from the 50 μM solution to obtain 
a 10 μM solution. 13.3 mg of BSA was then dissolved in 10 ml of each solution. 
The solutions were mixed thoroughly and allowed to stand at room temperature 
for approximately 20 min.
Spin filtration was performed using a swinging bucket rotor at 4000 rpm for 
6 min. The spin filters used were Amicon Ultra-15 centrifugal filters. The filtrates 
from each spin were collected to test for copper content in ICP-MS. Solutions 
for ICP-MS were prepared from both the original solutions and the filtrates. For 
each solution, 1 ml of solution was added to 1 ml of 4% HNO3 and 8 ml of 2% 
HNO3 to obtain a 1:10 dilution of each solution in 2% HNO3. Nitric acid used for 
ICP-MS analysis was OmniTrace trace-metal grade obtained from EMD Millipore 
Corporation. We used BSA to model copper binding histidine in solution and 
calculate relative dissociation constants (Kd) for each complex. Copper concentra-
tions were obtained using ICP-MS. The data was fit to Eq. (2) to estimate Kd and the 
number of binding sites, n.
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 [Cu] t −  [Cu] f  ___________
 [P] t 
 =  
n ∗  [Cu] f  _
 K d +  [Cu] f 
                                                     (2)
2.3 Zebrafish toxicity test
Following an approved BYU IACUC protocol, two AB wild-type male and 
female zebrafish were placed in an embryo media filled tank. The fish remained in 
a light and temperature-controlled facility until the following morning. Later that 
day, the fish were transferred into original tank. Embryos were moved into embryo 
media filled petri dishes (60 embryos/dish) and housed in an incubator for 2 days. 
Media was changed daily.
Fish embryos were dechorionated at 48 hpf. In a multi-well plate, 10 embryos 
were selected and 5 were added to each of two wells for each concentration with 
fresh embryo media. Drug solution (0–200 μM) was then added to test toxicity and 
observed over 5 days. Drug solutions were changed daily. After 5 days, the fish were 
scored using a morbidity scale (Table 1) indicating response, spine shape, edema, 
equilibrium, and death. The average for each complex was normalized using the 
maximal morbidity score of 50/well. The fish were then euthanized.
2.4 Ames testing
The Modified Ames ISO kit (Environmental Bio-Detection Products Inc., 
Mississauga, ON) was used with S. typhimurium TA100 (no S9 fraction).
The complexes were compared against the mutagenicity of a positive control 
(NaN3) and vehicle (water). The complexes were serially diluted 1:2 to compare the 
complexes’ mutagenic ability at each of six concentrations.
TA100 was hydrated and incubated with histidine overnight at 37°C. Following 
the kit’s instructions, in 96-well plates’ exposure solution, diluted bacteria mix, 
and serial two-fold dilutions of complexes were combined with reversion media 
containing Bromocresol Purple, which serves as a pH indicator to identify infected 
wells. The 96 well plates were incubated for 6 days at 37°C without agitation. When 
a sample is mutagenic, it will revert the bacteria to WT, causing the media to turn 
slightly acidic and show a yellow color.
The number of reverted wells with complex was compared to the average 
number of reverted wells in the negative control. Significance was calculated using 
a one-tailed t-test.
2.5 Simulations
The 2KQT M2 structure was used and oriented in a DMPC lipid bilayer with a 
center-of-mass harmonic constraint. The copper complexes were oriented such that 
the copper was near (~2.0 Å) at least one of the four imidazole nitrogens. Water 
molecules within 2.2 Å of the complexes were deleted. The protein-bilayer system 
was solvated with a tetragonal 60 Å × 60 Å × 90 Å water box as shown in Figure 2. 
The system was minimized for 1000 steps of steepest descent and heated to 
300 K. The M2 channel was equilibrated for 1 ns. The complexes were pulled using 
a constant force for 10 ps during the production runs. Frames were saved every 
50 steps, which is every 50 fs, of production for a total of 200 frames. Standard 
CHARMM version 37b1 parameters were used. Copper dihedral parameters were 
created using a 20 kcal/mol/rad2 energy penalty, which kept a conservatively rigid 
structure throughout the channel (Table A1).
The distance between imidazole nitrogens and copper on the complexes was 
calculated using CHARMM’s CORREL subroutine for each frame. The time for 
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each complex was recorded when the copper reached 30 Å away from the imidazole 
nitrogens. This distance was chosen to represent the complex leaving the mouth of 
the channel.
2.5.1 Decisions affecting pulling force
The pulling force for each of the complexes was determined by normalizing 
the pulling forces to a 2.34 nN pulling force on AMT. The 2.34 nN force allowed 
comparisons to be made between compounds as they left the channel on the 
10 ps timescale.
These steered molecular dynamics (SMD) simulations were analyzed by com-
puting the mean and standard deviation of five independent. The five independent 
Zebrafish scoring indicators
Morbidity points 0 1 2 3
Equilibrium Upright position Lying on side NA NA
Response Quick escape Sluggish escape No escape NA
Spine shape Straight Slightly curved Strongly curved NA
Edema None 1 place and 
minor
2 places or major 2 places and major
Death =10
Five fish per group in each of two wells.
Table 1. 
Scoring indicators observed daily for 5 days.
Figure 2. 
Solvated DMPC-2KQT system.
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simulations were assigned random starting velocities and then analyzed to explore 
the time needed to pass the 30 Å threshold relative to the starting point from the 
copper atom on the complex.
The analysis examined whether the pulling forces, copper ligation mechanism, 
or scaffold (CO, AMT, or neither), significantly affected the exit times relative to 
free Cu2+.
2.6 Miniplaque assays, resistance testing, and sequencing
MDCK cells were seeded into a six-well plate and grown in Dulbecco’s 
Modified Eagles Medium (DMEM, Sigma-Aldrich, St. Louis, MO) augmented by 
5% with fetal bovine serum (FBS, Hyclone, Logan, UT) until confluent. After 
48 h, the growth media was removed and replaced with DMEM. At this point the 
virus (A/CA/07/09) was introduced into the medium (200 pfu/ml) and allowed 
to adsorb for 1 h. The medium was then removed and replaced with fresh DMEM 
containing a specified concentration of complex and 5 ml of tosyl phenylala-
nyl chloromethyl ketone (TPCK)-treated trypsin (Thermo-Fischer Scientific, 
Waltham, MA, 1 mg/ml) was added to activate the virus. The plate was incubated 
at 33°C for 3 days. Then the medium was removed and centrifuged at 2000 rpm 
in order to remove cell debris. This virus-containing medium was then separated 
into 1-ml aliquots and frozen in Eppendorf tubes at −80°C. This process was 
repeated for each successive passage.
The concentration of virus was determined through an immunofluorescence 
assay (as previously described by [22]), which gave a multiplicity of infection 
(MOI) of 0.6. MDCK cells were seeded onto glass coverslips in vials containing 1 ml 
DMEM and trypsin in order to obtain 90% confluency after 24 h. The cells were 
allowed to grow overnight at 37°C, after which the growth medium was removed 
and replaced with DMEM. The sample of virus was then diluted by factors of 10, 
and the various dilutions of virus were stirred into the vials with coverslips. They 
grew at 33°C for 18 h. After this incubation period, the medium was removed, the 
cells were fixed with cold acetone (−80°C), and the coverslips were washed and 
stained with a fluorescein isothiocyanate labeled anti-IAV monoclonal antibody 
(Millipore Sigma, Burlington, MA, Cat. #5017). Excess antibody was washed off 
using a solution of 0.05% Tween20 in phosphate buffered saline and then again 
with distilled water. They were then viewed microscopically and individual infected 
cells (miniplaques) were counted.
This same process was followed in determining the new EC50 against the specific 
complex of each resistant strain. Except, 100 pfu of virus was used in each vial. 
Several different concentrations of the complex with which it was passaged were 
introduced into the vials, with concentrations ranging from 2 to 70 μM. The cells 
were infected with the virus in a solution of SEM rather than DMEM. The EC50 was 
calculated in KaleidaGraph using the Levenberg-Marquardt algorithm. The fitting 
parameters (sigmoidal function) were used to calculate the EC50 and the standard 
error of the mean.
To sequence the genome, the viral sample was concentrated 10-fold using a spin 
filter (VWR North America, Radnor, PA, Cat. #82031-352). After that, viral RNA 
was isolated using the QIAamp Viral RNA Mini Kit (Qiagen, Germantown, MD). 
The isolated RNA was stored at −20°C. RNA was then reverse-transcribed using 
Invitrogen’s Superscript III One-Step RT-PCR Platinum Taq HiFi kit (Thermo-
Fischer Scientific, Waltham, MA).
The resulting isolated DNA was stored at −20°C. The DNA was then 
amplified with PCR using the Phusion High-Fidelity PCR kit (New England 
Biolabs, Ipswich, MA). The solution was purified using Qiagen’s QIAquick PCR 
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Purification Kit (Qiagen, Germantown, MD). It was sequenced using custom 
forward (TGTAAAACGACGGCCAGTACGAAAAGCAGGTAG) and reverse 
(CAGGAAACAGCTATGACCAGTAGAAACAAGGTAGT) primers for the segment 
of the new DNA that codes for the M2 protein.
3. Results and discussion
3.1 Cytopathic effect assay
Although 1–4 had good potency against initial infections in the immunofluores-
cence (miniplaque) assay [15], the copper complexes had no effect in the cytopathic 
effect (CPE) assay with MDCK cells when dissolved in serumless DMEM. However, 
when the serumless DMEM was diluted with SEM, 1 (Figure 3) and to a lesser extent 
3 (data not shown) exhibited cell protection. Using a dual-sigmoidal function curve 
fit, 1 has an EC50 of 0.9 ± 0.08 μM and a CC50 of 5.8 ± 0.37 μM. The submaximal 
efficacy is due to high cytotoxicity. The selectivity index for 1 is 6.44, given by the 
ratio of the CC50 and EC50. The low EC50 compares favorably to the EC50 in the mini-
plaque assay, 6.7 ± 1.2 μM. In contrast, 3 has an EC50 greater than 100 μM, whereas 
its potency in the miniplaque assay was EC50 = 0.7 ± 0.1 μM, and 2 and 4–6 showed 
no effect, indicating that other factors were involved. The fact that some efficacy is 
observed when the medium is diluted with amino-acid free SEM suggests that free 
amino acids in non-dilute DMEM interfere with the copper complex efficacy.
3.2 Protein binding assay
To illustrate the potential of the metal complexes to bind to proteins, binding to 
BSA was measured in which a protein solution was mixed with various concentrations 
of a CuCl2 or copper complex solution. The copper content of the original sample 
Figure 3. 
CPE assay showing protective effect of 1 against A/WS/33 (M2 S31N) infection of MDCK cells using dilute 
medium (50% DMEM, 50% SEM). MOI 0.6; 48-h incubation.
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was measured and compared to that of the filtrate. Taking the volume proportions 
into account, the “free copper concentration” in the filtrate relative to the “total 
copper concentration” in the original sample was fitted to a model assuming that each 
protein molecule had n equivalent copper or copper complex binding sites. Table 2 
shows the best fit Kd values, assuming that each albumin monomer has n equivalent 
binding sites. The two parameters interacted and were therefore poorly constrained 
in the optimization of the deviations squared, but Table 2 indicates that the number 
of binding sites is well above 10, consistent with the count of 13 surface histidines 
in monomeric albumin (Figure A1). Complexes 1, 3, and 5 have larger Kd values 
compared to that of CuCl2 (59.1 μM). This indicates that the ligands on the metal 
complexes reduce the binding affinity for albumin binding sites, but also still allow 
for substantial binding. It is also consistent with the electrophysiology results for 
blocking through binding of copper complex to the His37 cluster in the M2 channel.
BSA has 13 surface histidines (Figure A1), however, all of the fits optimized n 
at >13 copper binding sites. This difference could suggest non-specific binding to 
other sites on BSA. The high Kd’s for the complexes relative to CuCl2 indicate that the 
complexes remain intact during binding to BSA. The binding the copper complexes 
to BSA is very weak compared to that of the M2S31N (AMT resistant) channel, where 
block was ~80% for 1 and 3 after 57 and 27 min perfusion, respectively. This sug-
gests that protein binding in vivo would be a minor concern. However, it is clear that 
binding by non-M2 proteins is detectable and, given their large quantity inside and 
outside the blood, they could limit access of the copper complexes to virus.
3.3 Zebrafish toxicity test
Toxicity was evaluated for zebrafish exposed to various concentrations of CuCl2 
or copper complex (1–5) added as methanolic solutions to the embryo bath medium 
starting 48 h post fertilization (Day 0) (Figure 4). At 200 μM copper complex on 
day 1, compounds 2, 4, and 5 show minimum toxicity effects, 1 and 3 show moder-
ate toxicity including slow response to stimulation, slightly curved spine, and minor 
edema, whereas CuCl2 causes major edema, strongly curved spine, no response 
to stimulation, and death. By day 2 at 200 μM, the toxicities of 1, 2, 4, and 5 have 
increased moderately but still only moderate spine curvature and minor edema, 
while 3 causes slow response to stimulation, strongly curved spine, and moderate 
to major edema. By days 3, 4, and 5 at 200 μM, all but 5 show low or no response, 
strongly curved spines, major edema, and some death. The MeOH vehicle controls 
showed statistically insignificant toxicity.
Compared to CuCl2, the copper complexes show less toxicity, suggesting that 
the ligands are coordinating to the copper and helping to reduce its toxicity through 
day 2 of high dosage. All of the copper complexes produce some toxicity in the 
zebra fish for all experimental concentrations, but compound 5 does not increase in 
Complex Kd (μM) Sites (n)
CuCl2 59.1 15
1 128.7 19
3 179.5 20
5 380 20*
Kd values for representative compounds 1, 3, and 5.*The value of n was not well-constrained and was therefore fixed 
during the curve fit.
Table 2. 
Binding to bovine serum albumin results.
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toxicity over time as much as the other complexes. This suggests further testing and 
modification of compound 5 could lead to a safe anti-influenza A therapeutic.
3.4 Ames testing
The mutagenicity of the copper complexes was tested using the Ames test. Table 3 
shows the percent reversion out of 48 wells of three complexes. They were tested for 
mutagenicity against S. Typhimurium TA100, which strain of bacteria allows a test for 
mutagenicity caused by base-pair substitution and oxidative damage. The percent 
of revertant wells (reversion rate) was compared against the negative control and 
found to be statistically insignificant (p > 0.01). The positive control (NaN3) had an 
average 91.7% reversion rate compared to the negative control’s average rate of 43.8% 
(p < 0.0001). Complexes 1, 3, and 4 did not show significant rate of reversion at any 
tested concentration compared to NaN3. The copper complexes showed approxi-
mately the same reversion rates as the negative control after 6 days. Therefore, they do 
not cause mutagenicity due to base-pair substitution or oxidative damage.
Figure 4. 
Zebrafish toxicity of copper complexes. CuCl2 (yellow), 1 (red), 2 (blue), 3 (green), 4 (magenta), 5 (black). 
(Arbitrary toxicity index, see Section 2).
Concentration (μM) Complex
1 3 4
500 42 42 50
250 42 42 30
125 31 52 33
62.5 31 41 38
31.25 52 58 67
15.63 56 52 56
0 35 46 50
Percent of reversion out of 48 wells for compounds 1, 3, and 4 for concentrations between 15 and 500 μM. 0 is water 
with no complex.
Table 3. 
Ames mutagenicity assay results.
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3.5 Resistance testing and sequence
Because the putative target for the metal complexes, the His37 quadruplex, 
is highly conserved in nature and functionally critical for vRNP uncoating, we 
explored the propensity for virus resistance formation with passaging in MDCK 
cell cultures. Because the incubation had to be done in DMEM, which is known 
to inhibit complex efficacy, we used higher concentrations of complexes for the 
incubations such that the efficacy of block was projected to be ~50%, thus creating 
a concentration where mutation could occur. Ten passages (~5 weeks) of incubated 
virus in DMEM dosed with increasing metal complex concentrations (ranging from 
50 to 100 μM) was chosen as a rigorous test. Resistance would be identifiable by an 
increase in miniplaque EC50 after passaging relative to the original value. As shown 
in Table 4, the new EC50 (column 3) is comparable to the original EC50 (column 2). 
Because none of the copper complexes significantly increased the EC50 after 5 weeks 
of incubation, we conclude that resistance is slow to develop. This contrasts with 
rapid resistance development when passaging with AMT [15].
The vRNA M segment was extracted from the passaged virus exposed to 3, 
sequenced and compared to A/CA/07/2009 using a reverse-BLAST mechanism. The 
only base mutation discovered was G749A, which translates to the amino acid muta-
tion G16E. This amino acid is positioned in the region of the channel entry that is 
outside of the membrane and unlikely to influence channel permeation. According 
to the results in the above table, this mutation did not confer resistance to this com-
pound. We consider the occasionally observed natural M2 mutant G34E to be likely 
to escape block by these complexes. Although we did not see resistance develop in our 
assays, a more direct assessment of the G34E site mutation using electrophysiology 
might be instructive about resistance potential for these compounds in future studies.
3.6 MD simulations
Constant force steered molecular dynamics (MD) simulations were carried out 
to explore the steric limitations on metal complex exit from the M2 transmembrane 
domain AMT binding site. A 2.34 nN force was used to pull the complexes pass the 
30 Å threshold and beyond the Val27 cluster within 10 ps. The 2.34 nN force gave 
a sufficient spread in leaving times to allow assessment of the ease of unbinding 
relative to AMT. For these simulations, the force was applied to the center-of-mass 
of the complex. Example trajectories for AMT (green) and 4 (yellow) are shown in 
Figure 5. The starting configurations (left) had the adamantyl groups of AMT and 
4 superimposed with the copper atom of 4 oriented down, close to H37. This bind-
ing configuration was used for all of the metal complexes. V27 and H37 are shown 
as reference points along the channel.
Complex Original A/CA/09 (μM) 10 passages with complex (μM)
1 6.9 ± 1.2 3.7 ± 0.5
2 4.9 ± 0.8 2.1 ± 1.1
3 0.7 ± 0.1 1.1 ± 0.4
4 11.6 ± 1.1 3.9 ± 6.8
5 8.2 ± 2.0 1.3 ± 0.2
6 4.4 ± 0.6 2.9 ± 0.3
DMEM was used for passage incubations and SEM for the miniplaque assays.
Table 4. 
Miniplaque EC50 ± SE (EC50) before (original) and after 10 passages of virus in MDCK cells.
11
Copper Complexes as Influenza Antivirals: Reduced Zebrafish Toxicity
DOI: http://dx.doi.org/10.5772/intechopen.88786
Table 5 shows the average time to leave from five independent simulations 
(identical starting configurations, but randomly assigned atomic velocities) for 
each complex to pass the 30 Å threshold. All metal complexes took longer to leave 
the channel than AMT. AMT exited the channel in 2.77 ps. Complex 4 interacts with 
the V27 side chain and was the slowest compound to leave the channel, with its leav-
ing time at 7.05 ps. By 4.4 and 6.75 ps, some distortion is seen on the protein subunit 
as 4 is pulled further out of the channel.
4. Conclusion
The copper complexes are relatively non-toxic in zebrafish embryos compared 
to CuCl2 over a 5-day period. Also, they are efficacious in a 3-day assay (but with 
limitations due to serum protein binding and amino acid interference), are non-
mutagenic compared to sodium azide, are slower to leave the M2 binding site 
compared to AMT, and, also compared to AMT, are not prone to resistance develop-
ment. In vivo they would face competition with binding to other proteins and the 
therapeutic window is small. However, complexation of copper could be pharmaco-
logically beneficial.
Further testing of these copper complexes should include isothermal titration 
calorimetry (ITC) experiments with influenza A M2 channel to obtain binding 
energies, two-electrode voltage clamp (TEVC) experiments to obtain rate constants 
of binding to M2, and testing in an animal model that more accurately represents 
the effects of the copper complexes on humans.
Complex Average time to leave (ps)
1 4.60 ± 1.14
2 6.85 ± 1.01
3 4.67 ± 1.07
4 7.05 ± 0.53
5 3.75 ± 0.89
6 4.00 ± 1.06
AMT 2.77 ± 0.26
Table 5. 
Average time to leave (±standard deviation) the channel with a 2.34 nN force applied to the compound’s 
center-of-mass.
Figure 5. 
Exit trajectories of AMT and 4 leaving M2 channel. Three of the four M2 TMD monomers from the simulation 
of 4 are displayed for reference. Valine 27 and Histidine 37 side chains are shown in grey, 4 is yellow and AMT 
is green. Both complexes are experiencing the same 2.34 nN pulling force.
Silver Nanoparticles - Health and Safety
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Appendix
See Figure A1 and Table A1.
CU parameters
Bond Kb (kcal/mol/Å2) B0 (Å)
CU-N 270.2 2.026
Angle Kθ (kcal/mole/rad2) θ0 (degrees)
CT1-NPH-CU 96.150 128.05
HB1-NPH-CU 30 123
CT2-NH3-CU 96.150 128.05
H-NPH-CU 0 180
NPH-CU-NH3 14.39 90
NPH-CU-NPH 14.39 90
Dihedral Φ (kcal/mole/rad2) Multiplicity Delta (degrees)
NPH-CU-NH3-CT2 20 1 92.30
CU-NPH-C2-OB 20 2 169.1
CU-NH3-CT1-CT2 20 1 −58.6
H-NPH-CU-NH3 20 2 157.9
NPH-CU-NPH-H 20 2 161.2
H-NPH-CU-NH3 20 2 157.9
C2-NPH-CU-NPH 20 2 18.8
CU-NPH-C2-CT2 20 2 8.0
CU-NH3-CT2-HA 20 3 90.20
C2-CT2-NH3-CU 20 2 −30.80
NPH-CU-NH3-H 20 2 161.2
Table A1. 
CHARMM copper parameters.
Figure A1. 
Bovine serum albumin view (RCSB 3V03). Histidine side chains are colored yellow.
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